Effect of exercise on plasma paraoxonase1 activity in rugby players: Dependance on training experience

References

• Nakamura N, Uzawa H, Haeda H, Inomoto T. Physical fitness, its contribution to serum high density lipoprotein. Atherosclerosis 1983;48:173–81.
   PubMed Web of Science ®Google Scholar
• Evelson P, Gambino G, Travacio M, Jaita G, Verona J, Maroncelli C, et al. Higher antioxidant defences in plasma and low density lipoproteins from rugby players. Eur J Clin Invest 2002;32:818–25.
   PubMed Web of Science ®Google Scholar
• Shneider CD, Barp J, Riberio JL. Oxidative stress after three different intensities of running. Can J Appl Physiol 2005;30:723–34.
   PubMedGoogle Scholar
• Anyanwu EC, Ehiri JE, Kanu I. Biochemical evaluation of antioxidant function after a controlled optimum physical exercise among adolescents. Int J Adolesc Med Health 2005;17:57–66.
   PubMedGoogle Scholar
• Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parma SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581–90.
   PubMed Web of Science ®Google Scholar
• Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000;275:3957–62.
   PubMed Web of Science ®Google Scholar
• Otocka-Kmiecik A, Orlowska-Majdak M. The role of genetic (PON1 polymorphism) and environmental factors, especially physical activity, in antioxidant function of paraoxonase. Postepy Hig Med Dosw 2009;3:668–77.
   Google Scholar
• Nakanisi M, Takanami Y, Maruyama T, Murata M, Motohashi Y, Nakano S, et al. The ratio of serum paraoxonase/arylesterase activity Rusing an improved assai for arylesterase activity to discriminate PON1R192 from PON1Q192. J Atheroscler Thromb 2003;10:337–42.
   PubMedGoogle Scholar
• Cabrera de Leon A, Rodriguez-Perez M de la C, Rodriguez-Benjumeda LM, Ania-Lafuente B, Brito-Diaz B, Muros de Fuentes M, et al. Sedentary lifestyle: physical activity duration versus percentage of energy expenditure. Rev Esp Cardiol 2007;60:244–50.
   PubMed Web of Science ®Google Scholar
• Otocka-Kmiecik A, Lewandowski M, Stolarek R, Szkudlarek U, Nowak D, Orlowska-Majdak M. Effect of single bout of ME on plasma antioxidant status and paraoxonase activity in young sportsmen. Redox Rep 2010;15:27–281.
   Google Scholar
• Ruta B, Otocka-Kmiecik A, Nowak D, Kujawa J. Antiatherosclerotic effect of exercise on the antioxidant properties of paraoxonase – a preliminary examination. Pol Ann Med 2012;19:84–8.
   Google Scholar
• Kasielski M, Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 2001;95:448–56.
   PubMed Web of Science ®Google Scholar
• Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of ‘antioxidant power’: the FRAP assay. Anal Biochem 1996;239:70–6.
   PubMed Web of Science ®Google Scholar
• Gabbett TJ. Physiological characteristics of junior and senior rugby league players. Br J Sports Med 2002;36:334–9.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Crouse SF, Goodpaster B, Kelley D, Moyna N, Pescatello L. The acute versus the chronic response to exercise. Med Sci Sports Exerc 2001;33:S438–45.
   PubMed Web of Science ®Google Scholar
• Tsakiris S, Karikas GA, Parthimos T, Tsakiris T, Bakogiannis C, Schulpis KH. Alpha-tocopherol supplementation prevents the exercise induced reduction of serum paraoxonase1/arylesterase activities in healthy individuals. Eur J Clin Nutr 2009;63:215–21.
   PubMed Web of Science ®Google Scholar
• Tomas M, Elosua R, Senti M, Molina L, Vila J, Anglada R, et al. Paraoxonase1-192 polymorphism modulates the effects of regular and acute exercise on paraoxonase1 activity. J Lipid Res 2002;43:713–20.
   PubMed Web of Science ®Google Scholar
• Otocka-Kmiecik A, Mikhalidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL – a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012;51(4):314–24.
   PubMed Web of Science ®Google Scholar
• Brites F, Zago V, Verona J, Muzzio ML, Wikinski R, Schreier L. HDL capacity to inhibit LDL oxidation in well-trained triathletes. Life Sci 2006;78:3074–81.
   PubMed Web of Science ®Google Scholar
• Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999;19:2214–25.
   PubMed Web of Science ®Google Scholar
• Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, et al. Paraoxonase activity in high density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 2005;90:1728–33.
   PubMed Web of Science ®Google Scholar
• Ferretti G, Bacchetti T, Masciangelo S, Bicchiega V. HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects. Obesity (Silver Spring) 2010;18:1079–84.
   PubMed Web of Science ®Google Scholar
• Rector RS, Warner SO, Liu Y, Hinton PS, Sun GY, Cox RH, et al. Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome. Am J Physiol 2007;293:E500–6.
   PubMed Web of Science ®Google Scholar
• Senti M, Tomas M, Vila J, Marruqat J, Elosua R, Sala J, et al. Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase gene: the REGICORegicor study. Atherosclerosis 2001;156:443–9.
   PubMedGoogle Scholar
• Camps J, Marsillach J, Joven J. Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity. Mini Rev Med Chem 2009;9:911–20.
   PubMed Web of Science ®Google Scholar
• Senti M, Tomás M, Anglada R, Elosua R, Marruqat J, Covas MI, et al. Interrelationship of smoking, paraoxonase activity, and leisure time physical activity: a population-based study. Eur J Intern Med 2003;14:178–84.
   PubMedGoogle Scholar
• Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler Thromb Vasc Biol 2000;20:2441–7.
   PubMed Web of Science ®Google Scholar
• Davis KA, Crow JA, Chambers HW, Meek EC, Chambers JE. Racial differences in paraoxonase-1 (PON1): a factor in the health of southerners. Environ Health Perspect 2009;117:1226–31.
   PubMed Web of Science ®Google Scholar
• Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000;101:2510–7.
   PubMed Web of Science ®Google Scholar
• Koncsos P, Seres I, Harangi M, Pall D, Jozsa L, Bajnok L, et al. Favorable effect of short-term lifestyle intervention on human paraoxonase-1 activity and adipokine levels in childhood obesity. J Am Coll Nutr 2011;30:333–9.
   PubMed Web of Science ®Google Scholar
• Resenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006;281:7657–65.
   PubMed Web of Science ®Google Scholar